Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (-)-cotinine | affects methylation | ISO | MYO1G (Homo sapiens) | 6480464 | Cotinine affects the methylation of MYO1G gene | CTD | PMID:22851337 | 1,2-dimethylhydrazine | increases expression | ISO | Myo1g (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in increased expression of MYO1G mRNA | CTD | PMID:22206623 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Myo1g (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of MYO1G mRNA | CTD | PMID:26377647 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of MYO1G mRNA | CTD | PMID:34747641 | 2-butoxyethanol | decreases expression | ISO | Myo1g (Mus musculus) | 6480464 | n-butoxyethanol results in decreased expression of MYO1G mRNA | CTD | PMID:19812364 | 4-hydroxyphenyl retinamide | decreases expression | ISO | Myo1g (Mus musculus) | 6480464 | Fenretinide results in decreased expression of MYO1G mRNA | CTD | PMID:28973697 | acetamide | increases expression | EXP | | 6480464 | acetamide results in increased expression of MYO1G mRNA | CTD | PMID:31881176 | aflatoxin B1 | increases methylation | ISO | MYO1G (Homo sapiens) | 6480464 | Aflatoxin B1 results in increased methylation of MYO1G exon and Aflatoxin B1 results in increased methylation of MYO1G gene | CTD | PMID:28458013 and PMID:30157460 | Aflatoxin B2 alpha | increases methylation | ISO | MYO1G (Homo sapiens) | 6480464 | aflatoxin B2 results in increased methylation of MYO1G exon | CTD | PMID:30157460 | all-trans-retinoic acid | increases expression | ISO | MYO1G (Homo sapiens) | 6480464 | Tretinoin results in increased expression of MYO1G mRNA | CTD | PMID:33167477 | amphetamine | decreases expression | EXP | | 6480464 | Amphetamine results in decreased expression of MYO1G mRNA | CTD | PMID:30779732 | antirheumatic drug | decreases expression | ISO | MYO1G (Homo sapiens) | 6480464 | Antirheumatic Agents results in decreased expression of MYO1G mRNA | CTD | PMID:24449571 | aristolochic acid A | increases expression | ISO | MYO1G (Homo sapiens) | 6480464 | aristolochic acid I results in increased expression of MYO1G mRNA | CTD | PMID:33212167 | benzo[a]pyrene | increases expression | ISO | MYO1G (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased expression of MYO1G mRNA | CTD | PMID:20064835 and PMID:30453624 | benzo[a]pyrene | affects methylation | ISO | MYO1G (Homo sapiens) | 6480464 | Benzo(a)pyrene affects the methylation of MYO1G exon and Benzo(a)pyrene affects the methylation of MYO1G promoter | CTD | PMID:27901495 and PMID:30157460 | benzo[a]pyrene | decreases methylation | ISO | MYO1G (Homo sapiens) | 6480464 | Benzo(a)pyrene results in decreased methylation of MYO1G 3' UTR | CTD | PMID:27901495 | benzo[a]pyrene | multiple interactions | ISO | Myo1g (Mus musculus) | 6480464 | [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MYO1G mRNA | CTD | PMID:27858113 | benzo[a]pyrene | increases expression | ISO | Myo1g (Mus musculus) | 6480464 | Benzo(a)pyrene results in increased expression of MYO1G mRNA | CTD | PMID:22228805 | benzo[a]pyrene | decreases expression | ISO | Myo1g (Mus musculus) | 6480464 | Benzo(a)pyrene results in decreased expression of MYO1G mRNA | CTD | PMID:21569818 | benzo[b]fluoranthene | increases expression | ISO | Myo1g (Mus musculus) | 6480464 | benzo(b)fluoranthene results in increased expression of MYO1G mRNA | CTD | PMID:26377693 | benzo[b]fluoranthene | multiple interactions | ISO | Myo1g (Mus musculus) | 6480464 | [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MYO1G mRNA | CTD | PMID:27858113 | benzo[e]pyrene | increases methylation | ISO | MYO1G (Homo sapiens) | 6480464 | benzo(e)pyrene results in increased methylation of MYO1G exon | CTD | PMID:30157460 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of MYO1G mRNA | CTD | PMID:25181051 more ... | bisphenol A | increases expression | ISO | Myo1g (Mus musculus) | 6480464 | bisphenol A results in increased expression of MYO1G mRNA | CTD | PMID:32156529 | bisphenol A | decreases expression | ISO | MYO1G (Homo sapiens) | 6480464 | bisphenol A results in decreased expression of MYO1G protein | CTD | PMID:33376534 | bisphenol A | increases methylation | EXP | | 6480464 | bisphenol A results in increased methylation of MYO1G gene | CTD | PMID:28505145 | buta-1,3-diene | decreases expression | ISO | Myo1g (Mus musculus) | 6480464 | 1 and 3-butadiene results in decreased expression of MYO1G mRNA | CTD | PMID:29038090 | cadmium atom | decreases expression | ISO | Myo1g (Mus musculus) | 6480464 | Cadmium results in decreased expression of MYO1G mRNA | CTD | PMID:23358151 | cadmium dichloride | affects expression | EXP | | 6480464 | Cadmium Chloride affects the expression of MYO1G mRNA | CTD | PMID:22110744 | carbon nanotube | affects expression | ISO | Myo1g (Mus musculus) | 6480464 | Nanotubes and Carbon analog affects the expression of MYO1G mRNA | CTD | PMID:25554681 | carbon nanotube | increases expression | ISO | Myo1g (Mus musculus) | 6480464 | Nanotubes and Carbon results in increased expression of MYO1G mRNA | CTD | PMID:25554681 | chloroprene | decreases expression | ISO | Myo1g (Mus musculus) | 6480464 | Chloroprene results in decreased expression of MYO1G mRNA | CTD | PMID:23125180 | chrysene | multiple interactions | ISO | Myo1g (Mus musculus) | 6480464 | [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MYO1G mRNA | CTD | PMID:27858113 | Cuprizon | increases expression | EXP | | 6480464 | Cuprizone results in increased expression of MYO1G mRNA | CTD | PMID:27523638 | dimethyl sulfoxide | increases expression | EXP | | 6480464 | Dimethyl Sulfoxide results in increased expression of MYO1G mRNA | CTD | PMID:22193206 | dimethylarsinic acid | multiple interactions | ISO | Myo1g (Mus musculus) | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MYO1G mRNA | CTD | PMID:34876320 | dioxygen | multiple interactions | EXP | | 6480464 | [Oxygen deficiency co-treated with Blood Glucose deficiency co-treated with Particulate Matter] results in increased expression of MYO1G mRNA | CTD | PMID:33729688 | diquat | decreases expression | ISO | Myo1g (Mus musculus) | 6480464 | Diquat results in decreased expression of MYO1G mRNA | CTD | PMID:36851058 | diuron | decreases expression | ISO | MYO1G (Homo sapiens) | 6480464 | Diuron results in decreased expression of MYO1G mRNA | CTD | PMID:35967413 | flutamide | increases expression | EXP | | 6480464 | Flutamide results in increased expression of MYO1G mRNA | CTD | PMID:24136188 | gentamycin | increases expression | EXP | | 6480464 | Gentamicins results in increased expression of MYO1G mRNA | CTD | PMID:22061828 | glafenine | increases expression | EXP | | 6480464 | Glafenine results in increased expression of MYO1G mRNA | CTD | PMID:24136188 | methapyrilene | increases methylation | ISO | MYO1G (Homo sapiens) | 6480464 | Methapyrilene results in increased methylation of MYO1G exon | CTD | PMID:30157460 | methylarsonic acid | multiple interactions | ISO | Myo1g (Mus musculus) | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MYO1G mRNA | CTD | PMID:34876320 | methylmercury chloride | increases expression | EXP | | 6480464 | methylmercuric chloride results in increased expression of MYO1G mRNA | CTD | PMID:31378766 | nefazodone | increases expression | EXP | | 6480464 | nefazodone results in increased expression of MYO1G mRNA | CTD | PMID:24136188 | nickel atom | increases expression | ISO | MYO1G (Homo sapiens) | 6480464 | Nickel results in increased expression of MYO1G mRNA | CTD | PMID:25583101 | nimesulide | increases expression | EXP | | 6480464 | nimesulide results in increased expression of MYO1G mRNA | CTD | PMID:24136188 | paracetamol | affects expression | ISO | Myo1g (Mus musculus) | 6480464 | Acetaminophen affects the expression of MYO1G mRNA | CTD | PMID:17562736 | perfluorooctanoic acid | increases expression | EXP | | 6480464 | perfluorooctanoic acid results in increased expression of MYO1G mRNA | CTD | PMID:19162173 | phenobarbital | increases expression | EXP | | 6480464 | Phenobarbital results in increased expression of MYO1G mRNA | CTD | PMID:19162173 | pirinixic acid | decreases expression | EXP | | 6480464 | pirinixic acid results in decreased expression of MYO1G mRNA | CTD | PMID:19162173 | pregnenolone 16alpha-carbonitrile | increases expression | EXP | | 6480464 | Pregnenolone Carbonitrile results in increased expression of MYO1G mRNA | CTD | PMID:19162173 | silicon dioxide | increases expression | ISO | Myo1g (Mus musculus) | 6480464 | Silicon Dioxide results in increased expression of MYO1G mRNA | CTD | PMID:29341224 | sodium arsenate | multiple interactions | ISO | Myo1g (Mus musculus) | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MYO1G mRNA | CTD | PMID:34876320 | sodium arsenite | multiple interactions | ISO | Myo1g (Mus musculus) | 6480464 | [sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MYO1G mRNA | CTD | PMID:34876320 | sodium arsenite | increases expression | ISO | Myo1g (Mus musculus) | 6480464 | sodium arsenite results in increased expression of MYO1G mRNA | CTD | PMID:36209798 | sodium dichromate | affects expression | EXP | | 6480464 | sodium bichromate affects the expression of MYO1G mRNA | CTD | PMID:22110744 | sulforaphane | decreases expression | ISO | MYO1G (Homo sapiens) | 6480464 | sulforaphane results in decreased expression of MYO1G mRNA | CTD | PMID:31838189 | tetraphene | increases expression | ISO | Myo1g (Mus musculus) | 6480464 | benz(a)anthracene results in increased expression of MYO1G mRNA | CTD | PMID:26377693 | tetraphene | multiple interactions | ISO | Myo1g (Mus musculus) | 6480464 | [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MYO1G mRNA | CTD | PMID:27858113 | titanium dioxide | increases expression | ISO | Myo1g (Mus musculus) | 6480464 | titanium dioxide results in increased expression of MYO1G mRNA | CTD | PMID:23557971 | titanium dioxide | decreases expression | ISO | Myo1g (Mus musculus) | 6480464 | titanium dioxide results in decreased expression of MYO1G mRNA | CTD | PMID:27760801 and PMID:29264374 | triptonide | increases expression | ISO | Myo1g (Mus musculus) | 6480464 | triptonide results in increased expression of MYO1G mRNA | CTD | PMID:33045310 | urethane | decreases expression | ISO | MYO1G (Homo sapiens) | 6480464 | Urethane results in decreased expression of MYO1G mRNA | CTD | PMID:28818685 | valproic acid | decreases methylation | ISO | MYO1G (Homo sapiens) | 6480464 | Valproic Acid results in decreased methylation of MYO1G gene | CTD | PMID:29154799 | |